Streetbeat News

WGS

GeneDx Holdings Corp.

http://www.genedx.com

Industry

Medical - Healthcare Information Services

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Open

72.05

Mkt cap

2.1B

Volume

262K

High

76.23

P/E Ratio

-24.41

52-wk high

89.11

Low

70.69

Div yield

N/A

52-wk low

1.76

GeneDx, a genomic insights company, will present at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025. The presentation will be available via webcast on their investor relations website.

Portfolio Pulse from

December 16, 2024 | 9:30 pm

A healthcare stock has achieved significant gains comparable to Nvidia's performance in less than a year. The article highlights the impressive growth of this stock, which is identified as WGS.

Portfolio Pulse from

November 16, 2024 | 10:15 am

GeneDx, a genomic insights company, will present key research findings at the 2024 ASHG annual meeting. Their presentations will include six platform presentations and five posters, showcasing data from over 700,000 clinical exomes and genomes.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

Goldman Sachs analyst Matthew Sykes maintains a Neutral rating on GeneDx Holdings (NASDAQ:WGS) but raises the price target from $54 to $70.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 5:02 pm

Wells Fargo analyst Brandon Couillard has maintained an Equal-Weight rating on GeneDx Holdings (NASDAQ:WGS) and raised the price target from $34 to $75.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 3:03 pm

Craig-Hallum analyst Bill Bonello has maintained a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raised the price target from $70 to $95.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:27 pm

U.S. stocks mostly rose with the Nasdaq gaining over 150 points. Phillips 66 shares fell 5% after Q3 results, despite beating EPS expectations. GlycoMimetics surged 172% on merger news. BIO-key rose 60% on a large order. GeneDx gained 46% on strong earnings. TransMedics and Janus International fell sharply on poor results.

Portfolio Pulse from Avi Kapoor

October 29, 2024 | 6:41 pm

U.S. stocks mostly rose with the Nasdaq gaining over 100 points. Pfizer reported strong Q3 earnings, beating expectations. GlycoMimetics surged on merger news, while BIO-key and GeneDx rose on positive developments. TransMedics and Janus International fell on disappointing earnings.

Portfolio Pulse from Avi Kapoor

October 29, 2024 | 5:17 pm

The article highlights significant intraday movements in healthcare stocks, with GlycoMimetics, Lixte Biotechnology, and GeneDx Holdings among the top gainers, while TransMedics Group and Coya Therapeutics are notable losers. The movements are influenced by recent earnings reports and market reactions.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 4:31 pm

GeneDx Holdings (NASDAQ:WGS) reported a narrower Q3 loss and increased revenues, leading to a significant stock price rise. The company beat earnings and revenue expectations, with a notable 77% growth in exome and genome test revenues. GeneDx also improved its adjusted gross margin and achieved positive adjusted net income. The company raised its 2024 revenue guidance, further boosting investor confidence.

Portfolio Pulse from Vandana Singh

October 29, 2024 | 3:11 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.